PTGX earnings date and last-quarter result: last quarter miss, P/E -75.17. Updated 2026-07-23.
Protagonist Therapeutics (PTGX) Research Hub
Protagonist Therapeutics (PTGX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 140.32 USD (+1.37%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -75.17, market cap 8.68B. This hub links to the full technical, earnings and options research available for PTGX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 140.32 USD (+1.37%) |
| 52-week range | 109.1 USD – 160.81 USD |
| Trend regime | Range |
| 14-day RSI | 52.1 (Neutral) |
| Trailing P/E | -75.17 |
| Market cap | 8.68B |
| Dividend yield | 0.00% |
Available research for PTGX
Covered Call on PTGX: how it works, illustrative setup around the real 140.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PTGX: how it works, illustrative setup around the real 140.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PTGX: how it works, illustrative setup around the real 140.32 USD price, max profit/loss, breakeven and when to use it. Educational.
PTGX technical analysis: range, last 140.32 USD, RSI 52.1, 52w range 109.1 USD–160.81 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is PTGX in?
Protagonist Therapeutics (PTGX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PTGX in an uptrend or downtrend?
As of 2026-10-26, PTGX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PTGX's trailing P/E ratio?
PTGX's trailing P/E is -75.17, with a market cap of 8.68B. See the earnings research page for full valuation detail.